Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruzinurad
- Development stage
- Phase 3
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ruzinurad (SHR4640) is a potent and highly selective small molecule inhibitor of the urate transporter 1 (URAT1), developed by Jiangsu Hengrui Medicine for the treatment of hyperuricemia and primary gout. By selectively blocking URAT1 in the proximal tubules of the kidney, ruzinurad inhibits the reabsorption of uric acid, thereby increasing its renal excretion and reducing serum uric acid levels. It has been evaluated in Phase II clinical trials both as a monotherapy and in combination with the xanthine oxidase inhibitor febuxostat, particularly for patients whose uric acid levels are inadequately controlled by febuxostat alone.
- Other names
- ruzinurad
02
Targets
URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on ruzinurad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruzinurad.